Assuming years is required, the following results were found.

  • MS Risk Nearly Doubles 15 Years Following Teen Concussion - Medscape

    a concussion during adolescence are at significantly elevated risk for multiple sclerosis (MS) later in life, especially 15 years or more following their head trauma, a large retrospective study suggests. This risk for developing MS over time nearly...

    https://mschristian.org/index.php/blog/ms-risk-nearly-doubles-15-years-following-teen-concussion-medscape
  • Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started Ocrevus after the double-blind period – – Interim analysis of...

    https://mschristian.org/index.php/blog/genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
  • Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

    from July 1, 2004, through August 31, 2017. Clinical evaluations and sample collection were performed annually for 5 years, then at different time points for up to 12 years, with a median follow-up duration of 10 (interquartile range, 7-11) years. Serum...

    https://mschristian.org/index.php/blog/association-between-serum-neurofilament-light-chain-levels-and-long-term-disease-course-among-patients-with-multiple-sclerosis-followed-up-for-12-years
  • Stem cell transplant reverses disabling MS-like disease - Medical Xpress

    reversed a debilitating neurological disease that causes half of the patients to go blind and lose the ability to walk five years after diagnosis. Most of the patients stayed better five years after the transplant and were able to avoid drug treatment...

    https://mschristian.org/index.php/blog/stem-cell-transplant-reverses-disabling-ms-like-disease-medical-xpress
  • #ECTRIMS2019 - Longer DMT Use and Female Sex Seen to Protect Against SPMS Conversion - Multiple Sclerosis News Today

    DMTs became available, studies indicated that nearly all (about 90%) of those with RRMS would transition to SPMS within 25 years. According to Iaffaldano, however, while these medicines have brought unprecedented benefits, it is too early to say how...

    https://mschristian.org/index.php/blog/ectrims2019-longer-dmt-use-and-female-sex-seen-to-protect-against-spms-conversion-multiple-sclerosis-news-today
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    EXPAND also investigated a subgroup of patients with active disease (n=779), defined as patients with relapses in the two years prior to the study and/or presence of Gd-enhancing T1 lesions at baseline. The baseline characteristics were similar except...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Arterys launches the first viewer-based AI Marketplace for medical imaging, fueling open innovation - P&T Community

    and make them instantly available worldwide. "Now you can build your AI app for free on Arterys and in minutes, instead of years, distribute them with the speed of the internet," said CEO and co-founder Fabien Beckers. The developer tools available on...

    https://mschristian.org/index.php/blog/arterys-launches-the-first-viewer-based-ai-marketplace-for-medical-imaging-fueling-open-innovation-p-t-community
  • Four-Year Study Confirms That Imaging the Eye with OCT Provides Window to MS Progression in the Brain and a Way to Track the Effects of Therapies

    by a collaborative team used advanced Optical Coherence Tomography (OCT) and MRI brain scans of 107 people with MS over four years to track the impacts of MS and to determine whether changes in nerve layers at the back of the eye mirror changes in...

    https://mschristian.org/index.php/blog/four-year-study-confirms-that-imaging-the-eye-with-oct-provides-window-to-ms-progression-in-the-brain-and-a-way-to-track-the-effects-of-therapies
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    assumptions of the model that the treatment effect is preserved, siponimod delayed the median time to wheelchair by 4.3 years in the overall population compared to placebo. Of course, extrapolation beyond the study period is a great limitation,”...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Multiple sclerosis treatments delay progression of the disease

    can delay progression of disability in Multiple Sclerosis. It showed that early treatment -- particularly within five years of onset -- delayed the secondary progressive stage of MS, which is characterised by an ongoing increase of disability. It showed...

    https://mschristian.org/index.php/blog/multiple-sclerosis-treatments-delay-progression-of-the-disease
  • Tecfidera (dimethyl fumarate)

    is classified as a disease-modifying therapy for MS. It reduces the risk of MS relapse by up to 49 percent over two years. It also reduces the risk of having worsening physical disability by about 38 percent. Tecfidera comes as a delayed-released oral...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • Aubagio (teriflunomide)

    same clinical trial showed that, compared with the placebo group, people who took Aubagio had: only one relapse every six years while taking the drug slower progression of disability (their physical disability didn't worsen as quickly) fewer new lesions...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Top 9 Drugs With the Biggest Price Increases Over 2 Years - Pharmacy Times

    Nine widely-used medications have experienced substantial price surges over the past 2 years, adding $5.1 billion to overall drug spending during this time period, according to a new report. Furthermore, 7 of these 9 drugs were found by the Institute...

    https://mschristian.org/index.php/blog/top-9-drugs-with-the-biggest-price-increases-over-2-years-pharmacy-times
  • Study shows the progression of multiple sclerosis can be slowed

    signals between the brain and the rest of the body. While nearly 1 million people in the United States over the age of 18 years live with a diagnosis of MS, and 2.3 million people globally have the condition, its causes remain a mystery. Women are two...

    https://mschristian.org/index.php/blog/study-shows-the-progression-of-multiple-sclerosis-can-be-slowed
  • Managing Hep C; A New Migraine Therapy: It's PodMed Double T!

    patients were randomly assigned to either undergo routine myotomy or to undergo POEM. They followed these individuals for 2 years. What they determined was there was success rate in 83% of thosethat had the POEM and 82% success rate in those that had...

    https://mschristian.org/index.php/blog/managing-hep-c-a-new-migraine-therapy-it-s-podmed-double-t
  • New insights into how immune system and inflammation play a role in PD

    indicating that the earliest stages of Parkinson's disease (PD) may occur in the gut have been gaining traction in recent years. In a review published in the Journal of Parkinson's Disease, Tomasz Brudek, PhD, evaluates evidence for the association...

    https://mschristian.org/index.php/blog/new-insights-into-how-immune-system-and-inflammation-play-a-role-in-pd
  • Common treatment for multiple sclerosis may prolong life

    that did not take the drug. This was particularly evident among MS patients who took beta interferon for more than three years. The study, which followed nearly 6,000 people with MS in Canada and France over a period of more than two decades, is the...

    https://mschristian.org/index.php/blog/common-treatment-for-multiple-sclerosis-may-prolong-life
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    themselves possible despite their condition. The following recommendations are based on my formal fellowship training; my 13 years of experience dedicated to MS clinical prac- tice; my review and contributions to the canon of MS literature; my...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction
  • Paul Mirabella Joins CorTechs Labs' Board of Directors - Business Wire

    board of directors as its newest member. Paul, who has worked as a senior executive in the healthcare industry for over 40 years, will play an active role in advising CorTechs Labs on matters including, but not limited to, business development strategy...

    https://mschristian.org/index.php/blog/paul-mirabella-joins-cortechs-labs-board-of-directors-business-wire
  • Alcohol Consumption Linked to Lower MS Disability

    Camilio and colleagues measured alcohol/wine consumption in servings per week for 908 patients (73% females, mean age 47±11 years, mean disease duration 13±9 years) enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB)...

    https://mschristian.org/index.php/blog/alcohol-consumption-linked-to-lower-ms-disability

Results 1 - 20 of 125
 
 

Follow Us on Twitter

Follow Us On Twitter - Image